Product Name:	Anti-Mouse PD-1 (CD279) [29F.1A12] In Vivo Antibody - Ultra Low Endotoxin
Product Code:	IVMB0032
Size:	1mg, 5mg, 25mg, 50mg, 100mg
Clone:	29F.1A12
Protein:	PD-1
Product Type:	Monoclonal Antibody
Synonyms:	PD1, Programmed Death-1, CD279
Isotype:	Rat IgG2a κ
Reactivity:	Mouse
Immunogen:	PD-1 cDNA followed by PD-1-Ig fusion protein
Applications:	B, CyTOF®, FC, IHC FF, PhenoCycler®, WB
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Endotoxin Level:	<0.5 EU/mg as determined by the LAL method
Purity:	≥98% monomer by analytical SEC >95% by SDS Page
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Product Code	Product Name	Endotoxin Level
IVMB0031	Anti-Mouse PD-1 (CD279) [29F.1A12] In Vivo Antibody - Low Endotoxin	Low
IVMB0032	Anti-Mouse PD-1 (CD279) [29F.1A12] In Vivo Antibody - Ultra Low Endotoxin	Ultra Low

Applications:	B, CODEX®, CyTOF®, FC, IHC FF, WB
Recommended Usage:	FC WB
Reactivity:	Mouse

Host Species:	Rat
Specificity:	Clone 29F.1A12 recognizes an epitope on mouse PD-1.
Antigen Distribution:	PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Immunogen:	PD-1 cDNA followed by PD-1-Ig fusion protein
Concentration:	≥ 2.0 mg/ml
Endotoxin Level:	<0.5 EU/mg as determined by the LAL method
Purity:	≥98% monomer by analytical SEC >95% by SDS Page
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.